Compare iShares MSCI Indonesia ETF (EIDO) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Indonesia ETF vs Neurocrine Biosciences Inc — how do they compare? iShares MSCI Indonesia ETF trades at $12.19, while Neurocrine Biosciences Inc trades at $171.54 (market cap $17.30B). The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, iShares MSCI Indonesia ETF nearer its low. Which is the better fit depends on your goals.
| EIDO | NBIX | |
|---|---|---|
52-Week High | $19.22 | $180.55 |
52-Week Low | $10.80 | $123.10 |
Market Cap | — | $17.30B |
Sector | — | Health |
Enterprise Value | — | $16.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The iShares MSCI Indonesia ETF (EIDO) trades at $12.205, up 1.12% on the day, while technical indicators signal a bearish trend with moving averages and an overbought short-term RSI. Recent news highlights Indonesia's economic initiatives, including a $15 billion AI-integrated free-meal plan and central bank rate hikes to support the currency. However, key financial ratios for the underlying fund holdings are unavailable in the provided data.
The outlook is mixed, balancing Indonesia's long-term GDP growth potential from government programs against near-term risks from currency volatility and geopolitical pressures. The ETF's dividend yield remains a draw, but a reported 27% dividend cut in 2025 signals underlying economic challenges for income-focused investors.
Neurocrine Biosciences (NBIX) trades at $172.14, up 0.09% with strong bullish technical signals and consistent earnings beats. The company demonstrates robust fundamentals with 98.17% gross margins and 21.55% net income margin, supported by revenue growth from $2.86B to $3.1B projected. Recent news highlights pipeline advancements including Phase 2 studies and positive clinical data presentations at ENDO 2026.
NBIX presents compelling investment potential with 86% analyst buy ratings and $195.75 consensus target, offering 14% upside. Key catalysts include Q2 earnings on July 30 and continued pipeline execution. Risks involve clinical trial outcomes and competitive pressures in neuroscience therapeutics. The stock's valuation at 26.47 P/E appears reasonable given growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
